A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
- Rawstron AC HMDS, St James's Institute of Oncology, Leeds, UK.
- Fazi C IRCCS San Raffaele Scientific Institute, Milano, Italy.
- Agathangelidis A IRCCS San Raffaele Scientific Institute, Milano, Italy.
- Villamor N Hospital Clínic, IDIBAPS, Barcelona, Spain.
- Letestu R Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
- Nomdedeu J Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Palacio C Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Stehlikova O Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
- Kreuzer KA University Hospital, Cologne, Germany.
- Liptrot S St James Hospital, Dublin, Ireland.
- O'Brien D St James Hospital, Dublin, Ireland.
- de Tute RM HMDS, St James's Institute of Oncology, Leeds, UK.
- Marinov I Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague, Czech Republic.
- Hauwel M University Hospital Geneva, Geneva, Switzerland.
- Spacek M General University Hospital, Prague, Czech Republic.
- Dobber J Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.
- Kater AP Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.
- Gambell P Peter MacCallum Cancer Centre, Melbourne, Australia.
- Soosapilla A Hematology and Flow Cytometry, Laverty Pathology, Sydney, Australia.
- Lozanski G Ohio State University Medical Center, Columbus, OH, USA.
- Brachtl G 3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.
- Lin K Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
- Boysen J Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
- Hanson C Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
- Jorgensen JL MD Anderson Cancer Center, Houston, TX, USA.
- Stetler-Stevenson M National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Yuan C National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Broome HE Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
- Rassenti L Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
- Craig F Un1iversity of Pittsburgh, Pittsburgh, PA, USA.
- Delgado J Hospital Clínic, IDIBAPS, Barcelona, Spain.
- Moreno C Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Bosch F Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Egle A 3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.
- Doubek M Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
- Pospisilova S Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
- Mulligan S Department of Haematology, Royal North Shore Hospital, Sydney, Australia.
- Westerman D Peter MacCallum Cancer Centre, Melbourne, Australia.
- Sanders CM Adaptive Biotechnologies, Seattle, WA, USA.
- Emerson R Adaptive Biotechnologies, Seattle, WA, USA.
- Robins HS Adaptive Biotechnologies, Seattle, WA, USA.
- Kirsch I Adaptive Biotechnologies, Seattle, WA, USA.
- Shanafelt T Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
- Pettitt A Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
- Kipps TJ Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
- Wierda WG MD Anderson Cancer Center, Houston, TX, USA.
- Cymbalista F Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
- Hallek M University Hospital, Cologne, Germany.
- Hillmen P Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
- Montserrat E Hospital Clínic, IDIBAPS, Barcelona, Spain.
- Ghia P IRCCS San Raffaele Scientific Institute, Milano, Italy.
- 2015-12-08
Published in:
- Leukemia. - 2016
Adolescent
Adult
Antigens, CD
Combined Modality Therapy
Europe
Female
Flow Cytometry
Follow-Up Studies
High-Throughput Nucleotide Sequencing
Humans
Immunophenotyping
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Neoplasm Staging
Neoplasm, Residual
Prognosis
Young Adult
English
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1038/leu.2015.313
- PMID 26639181
- Persistent URL
- https://sonar.ch/global/documents/245707
Statistics
Document views: 21
File downloads:
- fulltext.pdf: 0